Early Clinical Outcomes of High-Purity Type I Collagen as a Biologic Reinforcement in Selected Hernia Repair Scenarios: A Prospective Clinical Study
This prospective, single-arm clinical study evaluates the safety, feasibility, and early clinical outcomes of High-Purity Type I Collagen (HPTC; Surgicoll-Mesh®) when used as a biologic reinforcement in selected hernia repair scenarios where permanent synthetic mesh placement is undesirable. Outcomes focus on early postoperative safety, wound healing, and complication profiles over an 8-week follow-up period.
Indication: Hernia
Modality: protein therapy
Target: High-Purity Type I Collagen Mesh
Sponsor: Adichunchanagiri Institute of Medical Sciences, B G Nagara
Source URL: ClinicalTrials.gov
Source updated: Apr 23, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: High-Purity Type I Collagen Mesh
View original source fields
Condition raw: Hernia, Ventral Hernia, Incisional Hernia, İnguinal Hernia, Abdominal Wall Hernia, Surgical Site Infection, Postoperative Complications
Condition normalized: Hernia, Ventral Hernia, Incisional Hernia, İnguinal Hernia, Abdominal Wall Hernia, Surgical Site Infection, Postoperative Complications
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: High-Purity Type I Collagen Mesh
Target normalized: High-Purity Type I Collagen Mesh